Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX, page-29

First thoughts are it was a knee jerk reaction by traders which initially drove the stock down and took profits - not what anyone here was expecting i think you could safely say.

On face value the result reported of 3 of 21 doesn't 'look great' optically but that's just for the 50% reduction or greater which is miles above retrophin - i imagine the remaining 8 patients also would have a fair reduction but just not as great as 50% be good to get some colour on them

I would expect a brief consolidation period maybe the remainder of the week and into next where trading stock is cleaned up and the market is able to digest the significance of the results provided.

Hopefully it starts to get some traction with real biotech money out of the states and can push higher from here relatively quickly.